Low implementation of Xpert MTB/RIF among adults with HIV/TB co-infection in 19 low- and middle-income countries
Large UK study shows low rates of HIV testing, even among those who think they are at risk of HIV
Evidence for PrEP efficacy grows, but implementation presents challenges
Tenofovir alafenamide fumarate at what price? No more than $1000 a year above existing tenofovir formulation, says model
Two-drug ART with dolutegravir-lamivudine would be cost-effective and achieve substantial cash savings
US syringe funding ban impedes HIV and hepatitis C prevention
